StockInvest.us report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
Why XGN Stock slipped -1.26% Today — RQD Quant Desk Flash
Exagen Inc. (XGN) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is XGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Exagen Inc. (NASDAQ: XGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $8.59 (-1.26% 1D, market cap $210.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XGN ranks #639 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does XGN compare to TLSI and BDSX in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), XGN carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 58.3%, and ROIC of -35.0%. By comparison, TLSI (TriSalus Life Sciences Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $237.7M) and BDSX (Biodesix Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M). Among the 5-stock peer group, XGN leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for XGN?
▼
Per XGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001274737), Exagen Inc. generated $66.6M in revenue (+19.7% YoY), -$20.0M in net income, and -$14.3M in free cash flow against $58.0M in total assets and $22.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a XGN Turnaround Squeeze
While XGN currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.94) and Max Pain ($9.02) forces dealer call-delta covering toward $12.52.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why XGN Stock slipped -1.26% Today — RQD Quant Desk Flash
Exagen Inc. (XGN) slipped -1.26% to $8.59, trading at 64% of its 52-week range ($2.59 – $11.92). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 64% of its 52-week range ($2.59 – $11.92) with RSI-14 at 59.9 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $8.59 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 58.3% gross margin and $0 annual free cash flow.
Investing.com report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
CARLSBAD, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in and meet with investors at the follo
CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2026, before the mark
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XGN)
- ✓Walkthrough of XGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
XGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +19.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XGN. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XGN)
1. Head-to-Head Health Care Peer Comparison (XGN vs. TLSI, BDSX, BNR, YDES)
Industry: Medical Specialities (41 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Exagen Inc. (XGN) ranks #639 by composite RQD confidence (36/100, grade D-) and #567 by equity capitalization ($210.8M). Within this direct 5-issuer industry benchmark cohort, XGN leads on earnings valuation at N/A trailing P/E, while YDES leads on capital efficiency and profitability with -20.0% ROIC and 28.1% gross margin. YDES currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with XGN at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XGN
ACTIVE
Exagen Inc. | D- | 36/100 | — | 58.3% | -35.0% | -1.26% | $210.8M | Benchmark Subject |
| TLSI TriSalus Life Sciences Inc. | E | 31/100 | — | 84.6% | -35.0% | -4.14% | $237.7M | /tlsi-vs-xgn → |
| BDSX Biodesix Inc. | D- | 42/100 | — | — | -35.0% | -5.93% | $260.8M | /bdsx-vs-xgn → |
| BNR Burning Rock Biotech Limited | E | 20/100 | — | 74.7% | -35.0% | -1.36% | $116.5M | /bnr-vs-xgn → |
| YDES YD Bio Limited | D | 44/100 | — | 28.1% | -20.0% | +1.19% | $415.8M | /ydes-vs-xgn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001274737In its most recent audited fiscal period (FY2025, filed 2025-12-31), Exagen Inc. (XGN) reported GAAP revenue of $66.6M (+19.7% vs. FY2024 revenue of $55.6M , and +26.7% cumulative change since FY2023) , GAAP net income of -$20.0M, operating cash flow of -$13.6M, and free cash flow of -$14.3M (-3.4% YoY). On the balance sheet, XGN closed FY2025 with $58.0M in total assets against $22.3M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $66.6M | -$20.0M | -$13.6M | -$14.3M | $58.0M | $22.3M |
| FY2024 (FY) | 2024-12-31 | $55.6M | -$15.1M | -$13.3M | -$13.8M | $44.7M | $19.8M |
| FY2023 (FY) | 2023-12-31 | $52.5M | -$23.7M | -$14.5M | -$14.5M | — | — |
3. XGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs XGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Exagen Inc. (NASDAQ: XGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $8.59 (-1.26% 1D, market cap $210.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XGN ranks #639 in composite RQD confidence.
How does XGN compare to TLSI and BDSX in the Health Care sector?
Within the Health Care sector (Medical Specialities), XGN carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 58.3%, and ROIC of -35.0%. By comparison, TLSI (TriSalus Life Sciences Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $237.7M) and BDSX (Biodesix Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M). Among the 5-stock peer group, XGN leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for XGN?
Per XGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001274737), Exagen Inc. generated $66.6M in revenue (+19.7% YoY), -$20.0M in net income, and -$14.3M in free cash flow against $58.0M in total assets and $22.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is XGN trading relative to its 50-day, 200-day, and 52-week technical levels?
XGN last traded at $8.59 (-1.26% on volume of 394,020 shares), positioning the stock +8.19% above its 50-day simple moving average ($7.94) and +70.10% above its 200-day simple moving average ($5.05). Across its 52-week range of $2.59 to $11.92, XGN sits at the 64.3% percentile with a 14-day RSI of 59.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($7.52 to $9.66).
XGN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is XGN stock moving today?
Why XGN Stock slipped -1.26% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
XGN — Exagen Inc.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, XGN scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine (4 / 20): Return on invested capital is -35% and the free cash flow yield is -6.77%. This is the weakest pillar and signals that the business is not currently generating cash relative to the capital deployed. For a prospective investor, the upside case depends on a turnaround in operating cash generation that the source data does not show yet.
- Whale / 13F Flow (14 / 20): This pillar reflects institutional accumulation and options positioning. It is the strongest pillar, indicating some institutional interest, though the holder-level detail is not available in source data.
- Insider Conviction (3 / 20): This pillar reflects SEC Form 4 and Congressional PTR cluster flow. It scores low, and the news wire contains reported insider sales alongside an insider purchase (see Recent Catalysts). Mixed insider activity limits the conviction signal.
- Macro Regime Fit (7 / 20): Beta is 1.0, meaning the stock moves in line with the broader market, with added sensitivity to sector conditions. The score reflects limited defensive characteristics.
- Forensic Balance Sheet (8 / 20): Altman Z-Score is 0.2, Piotroski F-Score is 4 out of 9, and Debt/Equity is 1.28. These figures point to financial distress risk and weak balance-sheet quality. This is a material valuation tradeoff: any equity upside must be weighed against a leveraged, cash-consuming structure.
Taken together, the rating frames XGN as a high-risk, cash-consuming company. The valuation tradeoff for a prospective investor is that the stock's recent price strength and reported institutional interest must be weighed against weak profitability, negative cash flow, and a stressed balance sheet. This is an analytical framing, not personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $66.6M | $-14.1M | $-20.0M | N/A | $-14.3M | $32.2M | $22.3M |
| FY 2024 | $55.6M | $-13.6M | $-15.1M | N/A | $-13.8M | $22.0M | $19.8M |
| FY 2023 | $52.5M | $-22.8M | $-23.7M | N/A | $-14.5M | N/A | N/A |
Per the SEC financials, revenue grew from $52.5M in FY 2023 to $66.6M in FY 2025, while operating losses, net losses, and negative free cash flow persisted in each reported period. Operating margin is -21.1% and net margin is -30%. Return on invested capital is -35% per the market data section. The Altman Z-Score is 0.2 and the Piotroski F-Score is 4 out of 9, both per the Roarable RQD rating, indicating financial stress and weak fundamental quality. Cash of $32.2M against debt of $22.3M at FY 2025 shows a modest net cash position, though Debt/Equity of 1.28 indicates leverage relative to equity.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts feed:
- Catalyst (green): A TD Cowen price target raise from USD 10 to USD 11 is listed as a catalyst.
- Risk Watch (red): A Q2 2026 earnings headline notes a narrower-than-expected loss and a share price lift of 4.15%. It is flagged as a risk-watch item, and the source summary for that item is not a usable description of the company.
- Market Wire (yellow): Multiple items report director and CEO share transactions, including a director purchase of $104,440 in XGN stock, a CEO sale of 34,294 shares, and an initial ownership report of 2.6 million shares by a director. A StockInvest.us forecast item is also listed without further detail.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Open Questions
- What is the company's specific product portfolio, customer base, and revenue concentration?
- What are the forward earnings and EBITDA expectations, given that P/E and EV/EBITDA are not available?
- What are the terms, maturities, and covenants of the $22.3M debt, and can operating cash flow support it?
- What is the actual composition and size of the insider and institutional ownership positions?
- What drove the Q2 2026 narrower-than-expected loss, and does it reflect a durable improvement in cash generation?
XGN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Exagen Inc. (XGN) • Click "Debate This Headline" to argue it in the Roar Pit below
StockInvest.us report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Exagen Inc. (XGN) market action, institutional positioning, and fundamental catalysts.
CARLSBAD, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in and meet with investors at the follo
XGN Bull vs. Bear Conversation Board — What's Your Call at $8.59?
🔥 Official Bull vs. Bear Debate: Is XGN (D- • RQD 36/100) a Buy at $8.70?
Welcome to the XGN (Exagen Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on XGN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on XGN, but look at what you are paying: current EV/EBITDA multiples with 58.3% gross margins. Unless Exagen Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
XGN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on XGN, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $8.70 (52-wk range $2.59 - $11.92), any beat on forward guidance forces shorts and underweight funds to chase.